Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of BL-B01D1 + PD-1 therapy in locally advanced or metastatic urothelial carcinoma
CTR20241594Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in transitional cell carcinoma (TCC), sponsored by Biokin Pharmaceutical. Started Jun 2024; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on CTR20241594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241594.